These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19579828)

  • 1. Regulation of the statements in the information on drug metabolizing enzyme in the package insert--the present regulation and its history in Japan, the U.S. and the U.K.
    Watanabe S; Misu T; Kurihara T; Suzuki S; Sakurada T; Satoh N; Ueda S
    Yakushigaku Zasshi; 2008; 43(2):175-80. PubMed ID: 19579828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A 30-year history of the change in package insert for Japanese pharmaceutical medicines].
    Sasaki K; Kondo T
    Yakushigaku Zasshi; 2004; 39(2):276-85. PubMed ID: 16025649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiencies of product labeling directions for the preparation of radiopharmaceuticals.
    Hung JC; Ponto JA; Gadient KR; Frie JA; Aksamit CM; Enquist CL; Carrels KE
    J Am Pharm Assoc (2003); 2004; 44(1):30-5. PubMed ID: 14965150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research on Insufficient Information for Pharmaceutical Products].
    Tomita T
    Yakugaku Zasshi; 2017; 137(12):1497-1504. PubMed ID: 29199258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Eur J Clin Pharmacol; 2005 Aug; 61(7):531-6. PubMed ID: 16041596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug package inserts--varying information for the same medicines].
    Storflor JG; Pettersen LC; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2013 May; 133(9):955-9. PubMed ID: 23652143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network analysis of adverse drug interactions.
    Takarabe M; Okuda S; Itoh M; Tokimatsu T; Goto S; Kanehisa M
    Genome Inform; 2008; 20():252-9. PubMed ID: 19425139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 14. Current oral contraceptive use instructions: an analysis of patient package inserts.
    Williams-Deane M; Potter LS
    Fam Plann Perspect; 1992; 24(3):111-5. PubMed ID: 1628713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.
    Pai SA; Kshirsagar N
    J Clin Pharmacol; 2016 Oct; 56(10):1232-42. PubMed ID: 26873003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Physicians' Desk Reference. Problems and possible improvements.
    Cohen JS; Insel PA
    Arch Intern Med; 1996 Jul; 156(13):1375-80. PubMed ID: 8678706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of pharmacokinetic data provided in Japanese package inserts and interview forms focusing on urinary excretion of pharmacologically active species.
    Ohno Y; Kusama M; Hisaka A; Yanagihara Y; Suzuki H
    Yakugaku Zasshi; 2006 Jul; 126(7):489-94. PubMed ID: 16819270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of population pharmacokinetics in drug development and provision of the results to healthcare professionals
.
    Watanabe-Uchida M; Narukawa M
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):25-31. PubMed ID: 27841154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient package inserts: the proper prescription?
    Rowe HM
    Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
    [No Abstract]   [Full Text] [Related]  

  • 20. Inappropriate dosage instructions in package inserts.
    Fuchs J; Hippius M
    Patient Educ Couns; 2007 Jul; 67(1-2):157-68. PubMed ID: 17451909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.